Ambac (AMBC) was downgraded to sell from neutral at MKM Partners. $10 price target. The company is facing increased regulatory scrutiny, MKM said.
Bristol-Myers Squibb (BMY) was upgraded to buy at Jefferies. $69 price target. The company has an attractive clinical pipeline, but trades at a discount to its peers, Jefferies said.
Dexcom (DXCM) was upgraded to outperform from perform at Oppenheimer. $84 price target. The company is focused on big, long-term opportunities, Oppenheimer said.
Merck (MRK) was downgraded to underperform at Jefferies. $48 price target. Earnings estimates are below consensus, as Keytruda should continue to face pressure, Jefferies said.
Realogy (RLGY) was upgraded to outperform from neutral at Wedbush. $32 price target. The company is trading at a depressed valuation and is leveraged to rising existing home sales, Wedbush said.
United Technologies (UTX) was upgraded to outperform from neutral at Credit Suisse. $125 price target. Profit margin and earnings momentum are near a bottom, Credit Suisse said.
Williams (WMB) was upgraded to overweight from equal-weight at Morgan Stanley. $35 price target. Business has stabilized and management should now focus on the cost of capital, Morgan Stanley said.